Lifemd, Inc. (LFMD)
NASDAQ:LFMD
Want to see LFMD full AI Analyst Report?
LFMD Stock Chart & Stats
$2.78
-$0.50(-9.03%)
At close: 4:00 PM EST
$2.78
-$0.50(-9.03%)
Day’s Range― - ―
52-Week Range$2.56 - $15.84
Previous CloseN/A
Volume302.38K
Average Volume (3M)958.69K
Market Cap
$199.74M
Enterprise Value$209.15M
Total Cash (Recent Filing)$34.48M
Total Debt (Recent Filing)$6.17M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 06, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding48,362,510
10 Day Avg. Volume969,479
30 Day Avg. Volume958,693
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)6.65
Price to Sales (P/S)0.79
P/FCF Ratio-124.26
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit1.11
Enterprise Value/Ebitda-49.59
Forecast
1Y Price Target
$9.33Price Target Upside235.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.27
Revenue Forecast (FY)$222.05M
Bulls Say, Bears Say
Bulls Say
Subscriber Growth & Recurring RevenueConsistent, large subscriber additions strengthen LifeMD’s direct-to-patient recurring revenue base. A growing active subscriber pool improves predictability, enables higher lifetime value via cross-sell, and amplifies scale benefits for marketing efficiency and retention-driven margin improvement over the medium term.
High Gross Margins And Margin ExpansionSustained very high gross margins reflect a capital-light telehealth model and lower fulfillment costs from in-house pharmacy scaling. High contribution margin provides substantial room for operating leverage once fixed costs normalize and AI-driven efficiencies increase provider capacity and reduce per-patient operating expense.
Pharmacy Scale & Strategic Pharma PartnershipA three-year pharma co-marketing deal and licensed pharmacy capacity deepen distribution, diversify revenue beyond subscriptions, and integrate branded drug access into LifeMD’s platform. Preferred-dispenser status and expanded covered lives support durable revenue channels and faster insurance adoption, improving long-term unit economics.
Bears Say
Persistent GAAP Net LossesOngoing GAAP losses signal the company has not yet translated strong gross margins and subscriber growth into consistent bottom-line profitability. Continued net losses can erode equity, constrain reinvestment capacity, and increase reliance on external financing if operating improvements and marketing normalization do not materialize as planned.
Adjusted EBITDA InstabilityAdjusted EBITDA deterioration highlights that operating leverage is not yet realized and profitability is sensitive to marketing cadence and product-mix shifts. Dependence on a projected H2 ramp increases execution risk; failure to deliver consistent positive adjusted EBITDA would undermine cash reinvestment and long-term margin sustainability.
Revenue Volatility & Product-Mix TransitionSignificant revenue swings and a transition to branded therapies reduce near-term revenue per unit and complicate forecasting. Stabilizing unit economics requires insurance integration, scaled RCM and time to achieve branded-drug margins; until those structural pieces are proven, revenue volatility remains a material execution risk.
LifeMD News
LFMD FAQ
What was Lifemd, Inc.’s price range in the past 12 months?
Lifemd, Inc. lowest stock price was $2.56 and its highest was $15.84 in the past 12 months.
What is Lifemd, Inc.’s market cap?
Lifemd, Inc.’s market cap is $199.74M.
When is Lifemd, Inc.’s upcoming earnings report date?
Lifemd, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 38 days.
How were Lifemd, Inc.’s earnings last quarter?
Lifemd, Inc. released its earnings results on May 06, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.206 by $0.006.
Is Lifemd, Inc. overvalued?
According to Wall Street analysts Lifemd, Inc.’s price is currently Undervalued.
Does Lifemd, Inc. pay dividends?
Lifemd, Inc. does not currently pay dividends.
What is Lifemd, Inc.’s EPS estimate?
Lifemd, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Lifemd, Inc. have?
Lifemd, Inc. has 48,362,510 shares outstanding.
What happened to Lifemd, Inc.’s price movement after its last earnings report?
Lifemd, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.206. Following the earnings report the stock price went down -14.801%.
Which hedge fund is a major shareholder of Lifemd, Inc.?
Currently, no hedge funds are holding shares in LFMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LifeMD Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.33 (235.73% Upside)
$9.33 (235.73% Upside)
Blogger Sentiment
Bullish
LFMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 292.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-69.49%
12-Months-Change
Fundamentals
Return on Equity
-172.30%
Trailing 12-Months
Asset Growth
-4.74%
Trailing 12-Months
Company Description
Lifemd, Inc.
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological conditions, and more. Under its umbrella, LifeMD manages several specialized virtual care platforms: ShapiroMD is a telehealth brand focused on hair restoration, delivering virtual consultations, prescription medications, patented over-the-counter formulations, an FDA-cleared medical device, and custom-compounded topical treatments for both male and female hair loss. RexMD serves as a men's telehealth brand, providing virtual medical treatment from licensed providers for a wide array of male-specific health needs. LifeMD Primary Care offers a personalized, subscription-based virtual primary care solution, addressing routine, urgent, and chronic health management requirements. This mobile-centric platform integrates remote consultations, medication management, diagnostic services, and imaging referrals. Cleared is a telehealth service dedicated to offering personalized therapies for allergic, asthmatic, and immunological conditions. Nava MD stands as a skincare and tele-dermatology brand catering specifically to women, facilitating virtual access to dermatologists and other specialists for medical treatment. Additionally, the company provides PDFSimpli, a cloud-based software-as-a-service (SaaS) platform that empowers users to create, edit, convert, sign, and share PDF documents online. LifeMD distributes its offerings directly to individuals, via its own e-commerce channels, and through collaborations with external partners. Originally established in 1994 as Conversion Labs, Inc., the company rebranded to LifeMD, Inc. in February 2021 and is headquartered in New York City.
LFMD Company Deck
LFMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive operational narrative: record subscriber additions, strong momentum in weight management and Women’s Health, meaningful gross margin expansion, growing pharmacy and insurance scale, and a clear roadmap to leverage AI for operating leverage. These positives are balanced against near-term profitability pressures from a front-loaded marketing push, a product‑mix transition from compounded to branded drugs that dampened near‑term revenue/unit economics, a wider GAAP net loss, and negative adjusted EBITDA in Q1. Management reaffirmed full-year guidance and outlined drivers for a second‑half EBITDA ramp (insurance coverage expansion, pharmacy economics, cross-sell, and marketing normalization), indicating confidence in the outlook despite short-term investments and transitions.View all LFMD earnings summariesLFMD Stock 12 Month Forecast
Average Price Target
$9.33
▲(235.73% Upside)
Technical Analysis
Ownership Overview
17.51% Insiders
10.20% Mutual Funds
8.83% Other Institutional Investors
55.11% Public Companies and
Individual Investors